High-resolution imaging reveals how polymyxins trigger rapid shedding of bacterial armor
A team led by UCL (University College London) and Imperial College London researchers has shown for the first time how life-saving antibiotics called polymyxins pierce the armor of harmful bacteria. The findings, published in...
Modeling Complex Cancer and Viral Infection Mechanisms with Advanced Organoid Platforms
Register Now Panelists:
Amanda Linkous, PhD Research Associate ProfessorDepartment of PharmacologyVanderbilt University View Bio
Panelist ...
StockWatch: uniQure Shares Reach Five-Year High on “Game Changing” Huntington’s Data
The dazzling 36-month clinical data announced by uniQure (NASDAQ: QURE) showing a significant slowing of Huntington’s disease (HD) progression in patients treated with its gene therapy candidate AMT-130 was just one of several reasons...
New intramuscular mRNA vaccine offers easier alternative to treat neovascular eye diseases
An mRNA vaccine developed by researchers from Japan suppressed abnormal blood vessel growth or neovascularization in the retina of mouse models. Neovascularization is a condition that is caused by age-related macular degeneration (AMD), a...
Lonza’s Synaffix Collaborates with Qurient Therapeutics on Dual-Payload ADC Development
Synaffix, a Lonza company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs), entered into a licensing agreement with Qurient, a clinical-stage biopharmaceutical company based in South Korea, for...
Bridge Recombinase Platform Enables Megabase-Scale Human Genome Rearrangements
For decades, gene-editing science has been limited to making small, precise edits to human DNA, akin to correcting typos in the genetic code. Arc Institute researchers are changing that paradigm with the development of...
AI-guided platform improves design and efficiency of therapeutic nanoparticles
Biomedical engineers at Duke University have developed a platform that combines automated wet lab techniques with artificial intelligence (AI) to design nanoparticles for drug delivery. The approach could help researchers deliver difficult-to-encapsulate therapeutics more...
Groundbreaking discovery could transform leishmaniasis treatment
Leishmaniasis, a neglected tropical disease prevalent across 90 countries, affects approximately 12 million people worldwide, with 350 million more at risk of infection. Caused by unicellular parasites known as Leishmania protozoa, the disease commonly...
Senescent cell subtypes do not respond equally to treatment, study shows
A new research paper was published in Volume 17, Issue 8 of Aging-US on August 7, 2025, titled "Senescent cell heterogeneity and responses to senolytic treatment are related to cell cycle status during senescence induction." This study,...
Lonza Agrees to Scale Manufacturing for RION’s Exosome-Based Therapeutics
Lonza agreed to provide cGMP manufacturing and technical support for commercial scale production of RION’s Purified Exosome Product (PEP) drug substance for late phase clinical supply and beyond.
RION officials say the company developed a...
